Brian Klein
Recent Quotes
"INO confirms its VGX-3100 Phase 2 data readout is coming this summer."
—
Brian Klein, Stifel
(6/6/14)
more >
"ONC's Reolysin trial showed compelling tumor response improvement."
—
Brian Klein, Stifel
(12/13/12)
more >
"We anticipate ONC's trials will demonstrate compelling improvements on disease progression."
—
Brian Klein, Stifel
(11/9/12)
more >
"The reporting setback in ONC's head and neck study should lead to more robust results."
—
Brian Klein, Stifel
(9/12/12)
more >
"We are initiating coverage of ONC with a Buy rating and adding it to the Stifel Nicolaus Select List."
—
Brian Klein, Stifel
(8/29/12)
more >
"CYCC remains undervalued, with a compelling oncology asset and large commercial opportunity."
—
Brian Klein, Lazard Capital Markets
(3/30/12)
more >
